#USA #kidney transplant #Los Angeles, California #Randall Lawsuit #UNOS

California's Landmark Kidney Transplant Lawsuit

A pivotal lawsuit is underway in California that could reshape the landscape for kidney disease treatment. This case, titled Randall v. United Network for Organ Sharing, et al. (case no. 2:23-cv-02576-MEMF-MAA), highlights significant concerns regarding racial discrimination in the evaluation process for kidney transplant candidates.

Background of the Lawsuit

Since the year 2000, Black patients suffering from kidney diseases have been facing what the lawsuit describes as unequal treatment when it comes to being placed on national transplant waiting lists. The plaintiffs argue that organizations like the United Network for Organ Sharing (UNOS) and Cedars-Sinai Medical Center have employed methodologies that assess the kidney function of Black patients differently due to race. They allege that this has had dire consequences on how quickly Black patients can be placed on waiting lists for transplants.

The core of the arguments revolves around a calculation known colloquially as the “race-based coefficient.” This controversial formula allegedly makes the kidney health of Black patients appear more favorable than it genuinely is, resulting in delays in their access to critical transplant opportunities. As a result, many Black individuals have reportedly waited longer than necessary, potentially losing out on available donor kidneys.

Legal Arguments Presented

The plaintiffs claim that these practices violate California’s Unruh Civil Rights Act, which prohibits discrimination based on various attributes, including race. The lawsuit demands compensation of at least $4,000 for every incident of alleged discrimination, as well as coverage for legal fees. This could amount to significant financial reparation if the claims are validated.

On the other hand, both UNOS and Cedars-Sinai deny any wrongdoing, insisting that their methods were designed to protect patient interests and did not breach any laws. The dispute is now pending determination by the court, which will decide the legitimacy of these claims.

Who Can Join the Lawsuit?

The lawsuit has identified specific groups who may be eligible to join as plaintiffs. This includes Black kidney patients who registered on the national transplant list at California transplant centres from 2000 onwards. The court has given the green light for these individuals to file claims if they believe they have faced discrimination due to the race-based calculations.

Detailed guidance has been provided to potential plaintiffs on how to establish their status. Patients who are uncertain about their eligibility are encouraged to consult with the designated attorney, Matthew L. Venezia, who is representing the affected groups in this class-action case.

Options for Affected Individuals

Individuals impacted by this lawsuit have three options:

1. Stay in the Group: Those who choose not to take action will remain within the class and could share benefits from potential settlements or court rulings.
2. Opt for Individual Representation: Affected individuals may decide to hire their own attorneys at their expense and pursue claims independently.
3. Exclude Themselves: If individuals prefer to pursue separate claims without being part of this group, they can formally exclude themselves from the lawsuit.

Those interested in excluding themselves must do so by submitting a request by October 15, 2026, through specific channels provided in court notices.

Moving Forward

As this lawsuit progresses, it could potentially set a precedent for how racial dynamics play a role in healthcare practices, particularly in organ transplants. For Black patients in California and potentially beyond, the outcome of this case may prove instrumental in ensuring equitable treatment across the medical field.

For more information on how to proceed or inquire about eligibility, those affected can reach out through the contact details provided in the court’s notices or visit www.eGFRClassAction.com.